Related Experiment Video

Updated: Jan 9, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

817

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Himachandana Atluri1, Yasmin Abaza1, Jessica K Altman1

  • 1Division of Hematology and Oncology, Leukemia Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL.

Hematology. American Society of Hematology. Education Program
|December 5, 2025
PubMed

Insights

Triplet therapies combining hypomethylating agents, venetoclax, and targeted inhibitors show promise for acute myeloid leukemia (AML). These regimens are particularly beneficial for FLT3- and IDH1/2-mutated AML, overcoming resistance and improving outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) treatment faces challenges with drug resistance.
  • Triplet therapies offer a strategy to target multiple resistance pathways simultaneously.
  • Older AML patients unfit for intensive chemotherapy are a key focus for novel treatments.

Purpose of the Study:

  • To review the current treatment landscape for FLT3- and IDH1/2-mutated AML.
  • To evaluate the role of triplet regimens in these specific molecular subgroups.
  • To discuss challenges and future directions for combination therapies in AML.

Main Methods:

  • Review of current literature on triplet therapies in AML.
  • Focus on FLT3- and IDH1/2-mutated AML.
  • Analysis of outcomes in newly diagnosed and relapsed/refractory settings.

Main Results:

  • Triplet therapies demonstrate high rates of measurable residual disease-negative remissions.
  • Patients with FLT3-internal tandem duplication and IDH1 mutations show significant benefit.
  • Combination treatment improves outcomes compared to single-agent hypomethylating agents/venetoclax.

Conclusions:

  • Triplet regimens are a promising approach for FLT3- and IDH1/2-mutated AML.
  • Ongoing research is needed to address indefinite therapy and dose optimization.
  • These combinations offer new hope for challenging AML molecular subgroups.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K